



ITOG Annual Meeting

May 17—19, 2023

Universita Degli Studi Di Napoli, Federico II, Naples, Italy



ITOG 2023 Annual Meeting

Universita Degli Studi Di Napoli, Federico II

Naples, Italy

Wednesday, May 17 — Friday May 19, 2023



ITOG Annual Meeting

May 17—19, 2023

Universita Degli Studi Di Napoli, Federico II, Naples, Italy



Wednesday May 17, 2023 11:00AM–5:30PM

Organizational Meetings

Hotel Royal Continental Via Partenope, 38, 80121 Napoli NA, Italy

11:00—1:00 PM Corporate Liaison Council (CLC) (Live Stream)

Attendees: Board of Directors

Corporate Liaisons

Invited Members

1:00—1:30PM Lunch

1:30—3:30 PM ITOG Board of Directors

3:30—5:30 PM Protocol Committee

Welcome Reception

7:30— 9:30 PM Welcome Reception Hosted by ITOG

Open to all Members and Invited Guests

Hotel Excelsior Terrace

Via Partenope, Via Francesco Caracciolo 48 80121 Napoli, Italy



ITOG Annual Meeting

May 17—19, 2023

Universita Degli Studi Di Napoli, Federico II, Naples, Italy



Scientific Agenda Thursday May 18, 2023 8:00AM—6:00PM

8:00	Doors Open—Registration 1st Floor Lobby	
8:00–8:15	Opening Remarks	
	<ul style="list-style-type: none"> ◆ Gregory Randolph, President ◆ Domenico Salvatore & Martin Schlumberger, Hosts ◆ Mabel Ryder, Secretary Annual Meeting Chair ◆ Christine Spitzweg, Co-Chair 	
8:15–8:45	Keynote Session 1: Update on Melanoma Treatment	Paolo Ascierto
	Speaker Introduction: Domenico Salvatore	
8:45–9:00	Q & A	
9:00–9:30	Keynote Session 2: Trials for Rare Cancers, Part 2	Isabelle Borget
	Speaker Introduction: Martin Schlumberger	
9:30–9:45	Q & A	

9:45—10:00 Break

10:00–12:00	Session I : Anaplastic Thyroid Cancer	
	Moderators: Kate Newbold and Laura Locati	
	Debate/Discussion: Approaches for Unresected IVB BRAF Mutant ATC	
10:00—10:10	Chemoradiation	Keith Bible
10:10—10:20	Neoadjuvant BRAF/MEK/IO	Maria Cabanillas
10:20—10:40	Discussion	
10:40—11:25	Presentations	
10:40—10:55	Dabrafenib/trametinib resistance in BRAF mutant ATC	Marie-Claude Hofmann
10:55—11:10	Update in immune checkpoints in ATC	Jochen Lorch
11:10—11:25	Role of deiodinases in thyroid tumorigenesis	Domenico Salvatore
11:25—12:00	Brainstorming/Discussion/Clinical Trial Proposal Strategy	Moderator Mabel Ryder

12:00—1:00 Lunch

	Session II: Immune Therapies for Advanced Thyroid Cancers	
1:00—3:00	Moderators: Ramona Dadu and Efisio Puxeddu	
1:00—2:15	Presentations	
1:00—1:20	Immunotherapy for Advanced Thyroid Cancers – Potential and Challenges	Jena French
1:20—1:35	TSHR-CD3 BiTE	Jim Fagin
1:35—1:50	TSHR CART in ATC	Al Copland
1:50—2:05	Update on ICAM-1 Car-T	Samer Srour- virtual



Scientific Agenda
Thursday May 18, 2023 8:00AM—6:00PM

1:00—3:00	Session II: Immune Therapies for Advanced Thyroid Cancers (Continued) Moderators: Ramona Dadu and Efsio Puxeddu	
2:05—2:25	Trial Concepts: Eganelisib combination approaches for thyroid cancer ◆ BRAF+ ATC – D/T + anti-PD-1/PD-L1 + eganelisib ◆ BRAF- ATC – chemo + anti-PD-1/PD-L1 + eganelisib ◆ DTC – lenvatinib + anti-PD-1/PD-L1 + eganelisib	Jennifer Choe
2:25—3:00	Brainstorming/Discussion/Clinical Trial Proposal Strategy	Moderators Jena French Jennifer Choe
3:00— 3:15 Break		
3:15—5:15	Session III: Differentiated Thyroid Cancers (PTC, FTC) Moderators: Cosimo Durante and Sophie Leboulleux Debate/Discussion: 1st line therapy in BRAF mutant advanced DTC	
3:15—3:30	Dabrafenib with/without trametinib as initial therapy	Bhavana Konda
3:30—3:45	Lenvatinib as initial therapy	Lori Wirth
3:45—4:00	Discussion	
4:00—4:30	Presentations	
4:00—4:10	Updates in RAI redifferentiation	Alan Ho
4:10—4:20	BRAF-HER2 clinic trial	Eric Sherman
4:20—4:30	Pemetrex-carboplatin in treatment refractory DTC	Mabel Ryder
4:30—5:15	Brainstorming/Discussion/Clinical Trial Proposal Strategy	Moderator Steve Sherman
5:15—6:00	Business Meeting ITOG Members Only	Gregory Randolph Dwight Vicks

Dinner	Trattoria Toledo – Typical Neapolitan Seafood Trattoria Vico Teatro Nuovo, 47, 80134 Napoli NA, Italy An evening in Naples: a taste of local flavours Hosted by Domenico Salvatore and Martin SCHLUMBERGER
6:50—8:00	Meeting point @ Hotel Royal Continental Guided walking tour from the Hotel to the Trattoria through the historical Naples (<i>approx. 60 minutes</i>)
8:00	Dinner in Trattoria Back to the hotels by foot or by taxi



Scientific Agenda
Friday May 19, 2023 8:00AM—6:00PM

8:00—8:45 **Keynote Session 1: The Role of Radiotherapy in the Management of Thyroid Cancer** Ester Orlandi
 Speaker Introduction: Domenico Salvatore

8:45—9:30 **ETA Presentation: Reprogramming of myeloid cells/progenitors in patients with DTC** Romana Netea-Maier
 Speaker Introduction: Christine Spitzweg

9:30—9:45 **Gagel Awardee Presentation/Update** Herb Chen

9:45—10:00 Break

10:00—12:00 **Session IV: Medullary Thyroid Cancer**
 Moderators: Rosella Elisei and Andrew Gianoukakis

Debate/Discussion: RET mutant advanced and/or metastatic MTC: When to start selective RET inhibitors

10:00—10:10 Early approach Mimi Hu
 10:10—10:20 Delayed approach Ashish Chintakuntlawar
 10:20—10:40 Discussion

10:40—11:25 **Presentations: Optimizing Treatment Approaches in MTC**
 10:40—10:55 Mechanisms of RET resistance Rory Clifton-Bligh
 10:55—11:10 Alternatives to VEGFR MKIs and RET-specific inhibitors in advanced MTC Wayne Miles
 11:10—11:25 Role of Peptide Receptor Radionuclide Therapy in advanced thyroid cancer Wouter de Herder

11:25—12:00 **Brainstorming/Discussion/Clinical Trial Proposal Strategy** Moderator Matt Ringel

12:00—1:00 Lunch

1:00—3:00 **Session V: Oncocytic Thyroid Cancer (Hurthle Cell Thyroid Cancer)**
 Moderator: Bryan Haugen

1:00—1:20 Mitochondrial alterations and oncogenesis Ed Reznick-Virtual
 1:20—1:40 Updates in preclinical studies in Hurthle cell carcinomas/oncocytic carcinomas Ian Ganly
 1:40—2:00 Therapeutics – Immune therapies in HCC Jochen Lorch
 Alan Ho

2:00—3:00 **Brainstorming/Discussion/Clinical Trial Proposal Strategy**
Moderators
 Ian Ganly
 Eric Sherman



Scientific Agenda
Friday May 19, 2023 8:00AM—6:00PM

3:00—3:15

Break

3:15—4:30

ITOG Sponsored Clinical Trial Updates:

Current & Pending Trials

Moderator: Laura Boucai

- ◆ Selpercatinib ReDiff Trial
- ◆ Neoadjuvant Treatment with Selpercatinib in RET-Altered Thyroid Cancers
- ◆ NCI-ITOG 10240-CaboNivolpi in RAIR DTC
- ◆ A Phase 1 Trial of concurrent Intensity Modulated Radiation Therapy (IMRT) and Dabrafenib/Trametinib in BRAF Mutated Anaplastic or Poorly Differentiated Thyroid Cancer

Lori Wirth
Anastasios
Maniakas
Bhavana Konda
Sasan Fazeli

4:30—5:00

Wrap Up /Summary of Action Items/Adjourn

- ◆ Gregory Randolph, President
- ◆ Domenico Salvatore & Martin Schlumberger, Hosts
- ◆ Mabel Ryder, Secretary Annual Meeting Chair
- ◆ Christine Spitzweg, Co-Chair

ITOG MISSION STATEMENT

The mission of the International Thyroid Oncology Group is to catalyze a cure for the most challenging thyroid cancers through the collaborative efforts of our unique multidisciplinary team of leading physicians, scientists, and advocates to design, coordinate, and prioritize state-of-the-art clinical trials and correlative science.

Our members have led paradigm changing clinical trials for thyroid cancer patients. These trials have already resulted in the FDA approval of two new drugs for medullary thyroid cancer, and innovative new approaches for treating differentiated thyroid cancer. We are doctors, scientists, and patients whose lives and careers are focused on identifying new therapies for thyroid cancer.



Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer

Accrual Status: Accruing at MDACC, Open to accrual Feb 2021

Accrual Status: Accruing

Principal Investigator: Anastasios Maniakas, MD MD Anderson Cancer Center

Principle Investigator Email: Mzafereo@mdanderson.org

OSU 17277: A Phase 1 Trial of concurrent Intensity Modulated Radiation Therapy (IMRT) and Dabrafenib/Trametinib in BRAF Mutated Anaplastic or Poorly Differentiated Thyroid Cancer

Accrual Status: Accruing

Principal Investigator: Manisha Shah, MD The Ohio State University

Principle Investigator Email: Manisha.Shah@osumc.edu

NCI 10240: Phase II Study of Cabozantinib in combination with Nivolumab and Ipilimumab (CaboNivoIpi) in Patients with Radioiodine-refractory Differentiated Thyroid Cancer whose Cancer Progressed after 1 Prior VEGFR-Targeted Therapy

Accrual Status: Accruing

City of Hope Comprehensive Cancer Center, Moffitt Cancer Center, University of Kentucky Cancer Center, University of Pittsburgh Cancer Institute, Mayo Clinic, Rochester, University of Southern California, Dana Farber, Memorial Sloan Kettering

Mayo Clinic-Florida, University of Utah, University of Kansas

Sponsors: CTEP/NCI, ITOG

Principal Investigator: Bhavana Konda, MD; The Ohio State University Coordinating organization: The Ohio State University

Principle Investigator Email: Bhavana.Konda@osumc.edu

Publication/Presentation Status: ASCO 2020, ESMO 2020

Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

Accrual Status: Accruing

Sponsor: Loxo-Oncology Coordinating organization: LOXO-Oncology

Leader at ITOG: Lori Wirth and ITOG protocol-specific steering committee

Leader Email: Lwirth@mgh.harvard.edu

Publication Status: Pending (N Engl J Med 2020, 383:825-835; August 27, 2020)

Presentations: ASCO Jun 2018, ATA Oct 2018

COH 21308: A Phase 1 Trial of concurrent Intensity Modulated Radiation Therapy (IMRT) and Dabrafenib/Trametinib in BRAF Mutated Anaplastic or Poorly Differentiated Thyroid Cancer

Terry Williams City of Hope Rad Onc – 4/2023 Study up and running at COH (2-3 mo.) and opening at OSU and MDACC soon



ITOG Annual Meeting

May 17—19, 2023



Universita Degli Studi Di Napoli, Federico II, Naples, Italy

Guest Faculty

Paolo Ascierto, MD
Istituto Nazionale Tumori
IRCCS Fondazione

Isabelle Borget, PUPH
Gustave Roussy

Ian Ganly, MD
Memorial Sloan Kettering
Cancer Center

Wouter de Herder, MD PhD
Erasmus MC

Romana Netea-Maier, MD
Radboud University Medical
Center

Wayne Miles, PHD
Ohio State University

Ester Orlandi, MD
Fondazione CNAO

Ed Reznick, PhD—Virtual
Memorial Sloan Kettering
Cancer Center

Samer Srour, MB ChB, MS
MD Anderson Cancer Center

ITOG Member Faculty

Keith Bible, MD PhD
Mayo Clinic Rochester

Maria Cabanillas, MD
MD Anderson Cancer Center

Herb Chen, MD, FACS
University of Alabama-
Birmingham

Ashish Chintakuntlawar, MD,
PhD
Mayo Clinic Rochester

ITOG Member Faculty Cont'd

Ashish Chintakuntlawar, MD, PhD
Mayo Clinic Rochester

Jennifer Choe, MD
Vanderbilt University Medical Center

Rory Clifton-Bligh, MD PhD
The University of Sydney Royal North
Shore Hospital

Al Copland, PhD
Mayo Clinic Jacksonville

James Fagin, MD
Memorial Sloan Kettering Cancer Center

Sasan Fazeli
City of Hope Comprehensive Cancer Center

Jenna French, PHD
University of Colorado Denver,
Anschutz Medical Campus

Alan Ho, MD, PhD
Memorial Sloan Kettering Cancer Center

Marie-Claude Hofmann, MD
MD Anderson

Mimi Hu, MD
MD Anderson

Bhavana Konda, MD MPH
Ohio State University

Jochen Lorch, MD MSc
Dana Farber Cancer Institute

Anastasios Maniakas, MD
MD Anderson Cancer Center

Mabel Ryder, MD
Mayo Clinic Rochester

Matt Ringel, MD
Ohio State University

Domenico Salvatore, PhD
University of Naples

Eric Sherman, MD
Memorial Sloan Kettering Cancer Center

Steven Sherman, MD
MD Anderson

Lori Wirth, MD
Massachusetts General Hospital, Harvard

MODERATORS

Laura Boucai, MD
Memorial Sloan Kettering Cancer Center

Jennifer Choe, MD
Vanderbilt University Medical Center

Ramona Dadu, MD
MD Anderson Cancer Center

Cosimo Durante
University of Rome, Sapienza

Rossella Elisei, MD
University of Pisa, Italy

Jena French, PhD
University of Colorado

Ian Ganly, MD
Memorial Sloan Kettering Cancer Center

Andrew Gianoukakis, MD
University of California Los Angeles

Bryan Haugen, MD
University of Colorado Cancer Center

Sophie Leboulleux, MD
Hôpitaux Universitaires de Genève

Laura Locati, MD
Fondazione IRCCS Istituto Nazionale dei
Tumori, Italy

Kate Newbold, MD
The Royal Marsden NHS Foundation
Trust

Ef시오 Puxeddu MD PhD
University of Perugia

Matt Ringel, MD
Ohio State University

Mabel Ryder, MD
Mayo Clinic Rochester

Eric Sherman, MD
Memorial Sloan Kettering Cancer Center

Steve Sherman, MD
MD Anderson Cancer Center

Christine Spitzweg, MD
University Hospital Munich, Ludwig-
Maximilians-University Munich



ITOG Annual Meeting

May 17—19, 2023

Universita Degli Studi Di Napoli, Federico II, Naples, Italy



ITOG Executive Committee

Gregory Randolph MD, President
Massachusetts Eye and Ear

Mabel Ryder MD, Secretary
Mayo Clinic (Rochester)

Bryan Haugen, MD , Protocol Committee
University of Colorado Cancer Center

Dwight Vicks III, MBA CFO/Co-Founder
President, Vicks, Inc.

ITOG Board of Directors

Naifa Busaidy, MD, Membership Chair
MD Anderson Cancer Center

Andrew Gianoukakis, MD,
University of California, Los Angeles

Laura Fugazzola ,MD
University of Milan

Alan Ho MD, PhD, Correlative Sciences Chair
Memorial Sloan Kettering Cancer Center

Sophie Leboulleux, MD International Liaison
Hôpitaux Universitaires de Genève

Kate Newbold, MD
The Royal Marsden NHS

Yuri E. Nikiforov, MD PhD
University of Pittsburgh Medical Center

Carmelo Nucera, MD PhD
Harvard Medical School

Wendy Sacks, MD
Cedars-Sinai Medical Center

Julie Ann Sosa, MD, Finance Committee Chair
University of California, San Francisco

Christine Spitzweg, MD
Ludwig-Maximilians-University Munich

Mark Zafereo MD
MD Anderson Cancer Center

Annual Meeting Planning Committee

Mabel Ryder, MD, Chair
Mayo Clinic (Rochester)

Gregory Randolph MD
Massachusetts Eye and Ear

Domenico Salvatore, MD, Host
Università degli Studi di Napoli "Federico II

Martin Schlumberger MD Co-Host
Gustave Roussy

Christine Spitzweg MD, Co-Chair
University Hospital Munich, Ludwig-Maximilian
University Munich

Dwight Vicks III
Vicks Printing

Task Force Chairs

Marie Cabanillas, Anaplastic
MD Anderson Cancer Center

Jenna French, Immunotherapy
University of Colorado Denver,
Anschutz Medical Campus

Lori Wirth, Medullary
Massachusetts General Hospital

Cosimo Durante, Papillary
University of Rome, Sapienza

Eric Sherman, Hurthle Cell
Memorial Sloan-Kettering

ITOG Staff

Judy Dallas
Member Services Manager

Jessica Penny
Administrative Assistant

Brenda Mitchell
Finance Manager